Free Trial

Zealand Pharma A/S Q1 2023 Earnings Report

Zealand Pharma A/S logo
$75.60 -0.50 (-0.66%)
As of 03/31/2025 10:13 AM Eastern

Zealand Pharma A/S EPS Results

Actual EPS
-$0.54
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Zealand Pharma A/S Revenue Results

Actual Revenue
$1.96 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zealand Pharma A/S Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Remove Ads

Zealand Pharma A/S Earnings Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
See More Zealand Pharma A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zealand Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zealand Pharma A/S and other key companies, straight to your email.

About Zealand Pharma A/S

Zealand Pharma A/S (OTCMKTS:ZLDPF), a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

View Zealand Pharma A/S Profile

More Earnings Resources from MarketBeat